Caroline M. Loewy - 22 Mar 2024 Form 4 Insider Report for CymaBay Therapeutics, Inc.

Reporting relationship: Director
Issuer ticker: N/A
Reported as of: 22 Mar 2024
Net transaction value: $0
SEC form: 4
Accepted by SEC: 22 Mar 2024, 17:09:21 UTC
Prior SEC filing: 21 Feb 2024
Next SEC filing: 13 Jun 2024
Source filing: View source filing
Reporting owner signature: /s/ Paul Quinlan, as attorney-in-fact for Caroline Loewy

Key filing fact

Caroline M. Loewy filed Form 4 for CymaBay Therapeutics, Inc. on 22 Mar 2024.

Key facts

This page summarizes Caroline M. Loewy's Form 4 filing for CymaBay Therapeutics, Inc..
10 reported transactions and 10 derivative rows are listed below.
Accepted by SEC: 22 Mar 2024, 17:09.

Change

Previous filing in this sequence was filed on 21 Feb 2024.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CBAY transaction Derivative

Employee Stock Option (right to buy)

Disposed to Issuer

Transaction value
Shares: -30,000
Change %: -100%
Price
Shares after: 0
Date: 22 Mar 2024
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 30,000
Exercise price: $1.72
Footnotes: F1

CBAY transaction Derivative

Employee Stock Option (right to buy)

Disposed to Issuer

Transaction value
Shares: -15,000
Change %: -100%
Price
Shares after: 0
Date: 22 Mar 2024
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 15,000
Exercise price: $5.50
Footnotes: F1

CBAY transaction Derivative

Employee Stock Option (right to buy)

Disposed to Issuer

Transaction value
Shares: -7,500
Change %: -100%
Price
Shares after: 0
Date: 22 Mar 2024
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 7,500
Exercise price: $7.47
Footnotes: F1

CBAY transaction Derivative

Employee Stock Option (right to buy)

Disposed to Issuer

Transaction value
Shares: -16,000
Change %: -100%
Price
Shares after: 0
Date: 22 Mar 2024
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 16,000
Exercise price: $11.69
Footnotes: F1

CBAY transaction Derivative

Employee Stock Option (right to buy)

Disposed to Issuer

Transaction value
Shares: -27,705
Change %: -100%
Price
Shares after: 0
Date: 22 Mar 2024
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 27,705
Exercise price: $8.43
Footnotes: F1

CBAY transaction Derivative

Employee Stock Option (right to buy)

Disposed to Issuer

Transaction value
Shares: -49,245
Change %: -100%
Price
Shares after: 0
Date: 22 Mar 2024
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 49,245
Exercise price: $4.05
Footnotes: F1

CBAY transaction Derivative

Employee Stock Option (right to buy)

Disposed to Issuer

Transaction value
Shares: -32,000
Change %: -100%
Price
Shares after: 0
Date: 22 Mar 2024
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 32,000
Exercise price: $5.78
Footnotes: F1

CBAY transaction Derivative

Employee Stock Option (right to buy)

Disposed to Issuer

Transaction value
Shares: -67,000
Change %: -100%
Price
Shares after: 0
Date: 22 Mar 2024
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 67,000
Exercise price: $2.94
Footnotes: F1

CBAY transaction Derivative

Employee Stock Option (right to buy)

Disposed to Issuer

Transaction value
Shares: -25,000
Change %: -100%
Price
Shares after: 0
Date: 22 Mar 2024
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 25,000
Exercise price: $7.80
Footnotes: F1

CBAY transaction Derivative

Employee Stock Option (right to buy)

Disposed to Issuer

Transaction value
Shares: -14,010
Change %: -100%
Price
Shares after: 0
Date: 22 Mar 2024
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 14,010
Exercise price: $22.85
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

Caroline M. Loewy is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 1 footnote

Footnote F1

Pursuant to the Agreement and Plan of Merger, dated as of February 11, 2024, by and among CymaBay Therapeutics, Inc. ("CymaBay"), Gilead Sciences, Inc., a Delaware corporation ("Gilead"), and Pacific Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Gilead ("Purchaser"), among other things, Purchaser merged with and into the Company (the "Merger"). Accordingly, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration.